Adenosine A1 and A3 selective N-alkoxypurines as novel cytokine modulators and neuroprotectants

Drug Development Research

Volumn 45, Issue 3-4, 1998, Pages 214-221

  Knutsen, Lars J S ^a  

^a Cerebrus Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; N ALKOXYPURINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BRAIN PROTECTION; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RECEPTOR AFFINITY;

EID: 0032452643     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199811/12)45:3/4<214::AID-DDR19>3.0.CO;2-K     Document Type: Conference Paper

References (45)

1. Baraldi PG, Cacciari B, Spalluto G, JiX-d, Olah ME, Stiles G, Dionisotti S, Zocchi C, Ongini E, Jacobson KA. 1996. Novel N6-(substituted-phenylcarbamoyI)adenosine-5'-uronamides as potent agonists for AS adenosine receptors. J Med Chem 39:802-806.
2. Baraldi PG, Cacciari B, Pineda de Infantas MJ, Romagnoli R, Spalluto G, Volpini R, Costanzi S, Vittori S, Cristalli G, Melman N, Park K-S,Ji X-d, Jacobson KA. 1998. Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido .derivatives of adenosine-5'-N-ethyluronamide as AI and AS adenosine receptor agonists. J Med Chem 41:3174-3185.
3. Barbieri D, Abbracchio ME Salvioli S, Monti D, CossarizzaA, Ceruti S, Brambilla R, Cattabeni F, Jacobson KA, Franceschi C. 1998. Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem Int 32:493-504.
4. Borchardt RT, Hnber JA, Wu YS. 1976. Convenient preparation of S-adenosylhomocysteine and related compounds. J Org Chem 41:565-567.
5. Bowlin TL, Borcherding DR, Edwards CK, McWhinney CD. 1997. Adenosine AS receptor agonists inhibit macrophage tumor necrosis factor-cc production. Drug Dev Res 39:388-392.
6. Bruns RF, Daly JW, Snyder SH. 1980. Adenosine receptors in brain membranes: Binding of N .-cyclohexyl[ Hjadenosine and 1,3-diethyl-8-[3H]phenylxanfhine. Proc Natl Acad Sei USA 77:5547-5551.
7. Coward WR, Sagara H, Church MK. 1998. Asthma, adenosine, mast cells and theophylline. Clin Exp Allergy 28:42-46.
8. Davidsen SK, Summers JB. 1995. Inhibitors of TNF-rx synthesis. Expert Opin Ther Patents 5:1087-1100.
9. DeNinno ME 1998. Adenosine. Annu Rep Med Chem 33:111-120.
10. DunwiddieTV, Abbracchio M P, Bischofbcrger N, BrundegeJM, Buell G, Collo G, Corsi C, Diao L, Kawashima E, Jacobson KA, Latini S, Lin RCS, North RA, Pazzagli M, Pedata E Pepeu GC, Proctor WR, Rassendren F, Surprenant A, Caltabeni E 1997. Purinoceptors in the central nervous system. Drug Dev Res 39:361-370.
11. Edwards CK, Zhou T, Zhang J, Baker TJ, De M, Long RE, Borcherding DR, Bowlin TL, Bluethmann H, Mountz JD. 1996. Inhibition of superantigen-induced proinllammatory cytokine production and inflammatory arthritis in MRL-Ipr/lpr mice by a transcriptional inhibitor of TNF-a. J Immunol 157:1758-1772.
12. Feuerstein GZ, Wang X, Barone FC. 1997. Inflammatory gene expression in cerebral ischemia and trauma: Potential new therapeutic targets. Ann NY Acad Sei 825:179-193.
13. Foster SJ, McCormick LM. 1993. Tumor necrosis factor a production by rat blood and its ex vivo pharmacological modulation. Agents Actions 39:C61-C63.
14. Fredholm BB, Abbracchio MP, Bumstock G, Daly JW, Harden TK, Jacobson KA, Williams M. 1994. Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143-156.
15. 6-benzyladenosine-o'-uronamides as As-selective adenosine agonists. J Med Chem 37:636-646.
16. IJzerman AP, von Frijtag JK, Vittori S, Cristalli G. 1994. Purine-substituted adenosine derivatives with small N -substituents as adenosine receptor agonists. Nucleosides Nucleotides 13:2267-2281.
17. Imai K, Nohara A, Honjo M. 1966. Synthesis of purine nucleosides using iodine as catalyst. Chem Pharm Bull 14:1377-1381.
18. Jacobson KA. 1998. Adenosine AS receptors: Novel ligands and paradoxical effects Trends Fharmacol Sei 19:184-191.
19. Jacobson KA, Kirn HO, Siddiqi SM, Olah ME, Stiles GL, von Lubitz DKJE. 1995. As-adenosine receptors: Design of selective ligands and therapeutic prospects. Drugs Future 20:689-699.
20. Jacobon KA, van Galen PJM, Williams M. 1992. Adenosine receptors: pharmacology, structure-activity relationships and therapeutic potential. J Med Chem 35:407-422.
21. 3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A£ receptors in rat brain. J Pharm Exp Ther 251:888-893.
22. j Kirn HO, Ji X-d, Siddiqi SM, Olah ME, Stiles GL, Jacobson KA. [ 1994. 2-Substitution of N6-benzyladenosine-5'-uronamides en| hances selectivity for AS adenosine receptors. J Med Chem 37:3614-3621.
23. Klitgaard H, Knutsen LJS, Thomsen C. 1993. Contrasting effects of adenosine A] and A2 receptor ligands in different chemoconvulsive models. Eur J Pharmacol 224:221-228.
24. Knutsen LJS, Lau J. 1993. Adenosine derivatives. WO 93/23417 (25 November 1993); US 5,430,027 {July 4, 1995).
25. Knutsen LJS, Lau J, Sheardown MJ, Thomsen C. 1993. The synthesis and biochemical evaluation of new AI selective adenosine receptor agonists containing a 6-hydrazinopurine moiety. Bioorg Med Chem Lett 3:2661-2660.
26. Knutsen LJS, Lau J, Eskesen K, Sheardown MJ, Thomsen C, Weis JU, Judge ME, Klitgaard, H. 1995. Anticonvulsant actions of novel and reference adenosine agonists. In: Belardinelli L, Pelleg A, editors. Adenosine and adenine nucleotides: From molecular biology to integrative physiology. Boston: Kluwer, pp 479-487.
27. Knutsen LJS, Olsen UB, Bowler AN. 1997. Preparation of nucleosides for treating disorders related to cytokines in mammals. WO 97/33591 (18 September).
28. Knutsen LJS, Olsen UB, Roberts SM, Varley DR, Bowler AN. 1998. Preparation of N-alkoxyadenosines as cytokine inhibitors. WO 98/01459 (15 Januar-1998).
29. See also (1998): Adenosine A3 receptors and cytokine production. Expert Opin Ther Patents 8:1049-1051.
30. Lau J, Knutsen LJS. 1995. Preparation of adenosine derivatives for treatment of central nervous system diseases. WO 95/07921 (23 March).
31. Le Vrattx V, Chen YL, Masson I, De Sousa M, Giroud JP, Florentin I, Chauvelot-Moachon L. 1993. Inhibition of human monocyte TNF production by adenosine receptor agonists. Life Sei 52:1917-1924.
32. Linden J. 1994. Cloned adenosine AS receptors: Pharmacological properties, species differences and receptor functions. Trends Pharmacol Sei 15:298-306.
33. McWhinney CD, Dudley MW, Bowlin TL, Peet NP, Schook L, Bradshaw M, De M, Borchercling DR, Edwards CK. 1996. Activation of adenosine AS receptors'on macrophages inhibits tumor necrosis faclor-a. Eur J Pharmacol 310:209-216.
34. Mogensen JE Roberts SM, Bowler AN, Thomsen C, Knutsen LJS. 1998. The synthesis of new adenosine AS selective ligands containing bioisosteric isoxazoles. Bioorg Med Chem Lett 8:1767-1770.
35. Peraldi P, Spiegelman B. 1998. TNF-α and insulin resistance: Summar)1 and future prospects. Mol Cell Biochem 182:169-175.
36. Poulsen S-A, Quinn RJ. 1998. Adenosine receptors: New opportunities for future drugs. Bioorg Med Chem 6:619-641.
37. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. 1996. Inhibition of TNF-α expression by adenosine. Role of AS adenosine receptors. J Immunol 156:3435-3442.
38. Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG. 1993. Molecular cloning and characterization of the human As adenosine receptor. Proc Natl Acad Sei USA 90:10365-10369.
39. Sheardown MJ, Suzdak PD, Nordholm L. 1993. AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed for 24 h. Eur J Pharmacol 236:347-353.
40. Sheardown MJ, Hansen AJ, Thomsen C, Judge ME, Knutsen LJS. 1995. Novel adenosine agonists: A strategy for stroke therapy. In: Grotta J, Miller L, Buchan AM, editors. Ischémie stroke: Recent advances in understanding and therapy. Southborough, MA: International Business Communications, p 187-214.
41. Siddiqi SM, Jacobson KA, Esker JL, Olah ME, Ji X-d, Melman N, Tiwari KN, Secrist JA, Schneller SW. 1995. Search for new purine- and ribose-modified adenosine analogs as selective agonists and antagonists at adenosine receptors. J Med Chem 38:1174-1188.
42. Thomsen C, Valsborg JS, Foged C, Knutsen LJS. 1997. Characterization of [3H]-N-[R-(2-BenzothiazolyI)thio-2-propyI]-2-chloroadenosine ([3H]-NNC 21-0136) binding to rat brain: Profile of a novel selective adenosine receptor agonist for adenosine AI receptors. Drug Dev Res 42:86-97.
43. Von Lubitz DKJE, Lin RC-S, Popik P, Carter ME Jacobson KA. 1994. Adenosine AS receptor stimulation and cerebral ischemia. Eur J Pharmacol 263(l/2):59-67.
44. Wlliams M, Summers JB. 1994. Septic shock: The continuing challenge for an effective therapy. Expert Opin Invest Drugs 3:1051-1056.
45. Zhou QY, Li CY, Olah ME, Johnson RA, Stiles GL, Civelli O. 1992. Molecular cloning and characterization of an adenosine receptor: The A3 adenosine receptor. Proc Natl Acad Sei USA 89:7432-7436.